[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"laxity-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:laxity-skin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,75,105,125,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635893","evaluate-the-safety-and-efficacy-of-age-serum-in-post-menopausal-patients-on-hormone-replacement-therapy-taking-glucagon-like-peptide-1-agonist-100635893",false,"NCT07558603","Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist","A Prospective, Single Center, Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)\n2. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.\n3. Adult women aged 45-65 years.\n4. Fitzpatrick skin types I-VI.\n5. Current treatment with a stable dose of any GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least the last 3 months\n6. Must be willing to sign a photography release and ICF,and complete the entire course of the study.\n7. Subjects in good general health based on the investigator's judgment and medical history.\n\nExclusion Criteria:\n\n1. Non post-menopausal state.\n2. Any uncontrolled systemic disease.\n3. History of autoimmune connective tissue disease.\n4. Current use of immunosuppressive medication.\n5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n6. Active dermatitis or active infection in the proposed treatment area.\n7. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n8. Microneedling treatments of the face and neck during the 1 month period before study treatment\n9. Laser and light based device treatments of the face and neck. Ablative lasers 6-month period before study treatment, and 3-month period for non-ablative lasers.\n10. Any neurotoxin injection to the face or neck during the 6-month period before study treatment\n11. Subjects using any treatment skincare products must discontinue use of these products 2 weeks before the start of participating in this clinical study and for the duration of the study.\n12. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n14. History of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, history of smoking.\n15. Inability to ambulate following the procedure.\n16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",true,"FEMALE","45 Years","65 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires\u002Fassessments, photography, skin imaging, and reported adverse reactions.",[28],"Laxity; Skin",[30,31,32,33,34,35,36],"GLP1","HRT","Hormone replacement therapy","weight loss","skin laxity","skin texture","skin tone","NOT_YET_RECRUITING","2026-04-24",{"date":40,"type":41},"2026-04-30","ACTUAL",{"date":43,"type":22},"2026-04-20",{"date":45,"type":22},"2026-11-30",{"name":47,"class":48},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100624731","prospective-clinical-evaluation-of-the-safety-and-performance-of-the-aesthetic-medical-device-mec-regenerate-injectable-recombinant-collagen-based-product-100624731","NCT07413445","Prospective Clinical Evaluation of the Safety and Performance of the Aesthetic Medical Device MEC REGENERATE® (Injectable Recombinant Collagen-based Product)","Inclusion Criteria:\n\n* Both sexes;\n* Caucasian race;\n* Aged between 35 and 65 years;\n* Non-smokers;\n* Willing and able to return to the study site for post-procedural assessments;\n* Agree to attend all study visits without makeup;\n* Agree not to change their habits regarding diet, physical activity, facial makeup, cosmetics, and facial cleansing products;\n* Agree to avoid intense UV exposure (UV sessions or sunbathing) during the entire study period without adequate sun protection;\n* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use;\n* Agree to sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy (applicable only to non-menopausal female subjects);\n* Breastfeeding (applicable only to non-menopausal female subjects);\n* Smokers;\n* Alcohol abuse and\u002For drug use;\n* Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study;\n* Body mass index (BMI) variation of ±1 during the study period;\n* History of aesthetic skin treatments (biomaterial implants, facelift, botulinum toxin injections, laser therapy, chemical peels) within 6 months prior to the study start;\n* Previous permanent filler treatments;\n* Changes in normal habits related to diet, physical activity, facial cosmetics, facial cleansing, and makeup within one month prior to the study;\n* Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline);\n* Predicted poor compliance with study protocol;\n* Participation in a similar study currently or within the past 9 months;\n* Dermatological clinical conditions that could interfere with aesthetic outcomes;\n* Chronic neurological, immunological, metabolic, cardiovascular, pulmonary, renal, or oncological diseases;\n* Current pharmacological treatment with: Anticoagulants, antiplatelet agents, antihistamines, topical or systemic corticosteroids, narcotics, antidepressants, immunosuppressants (except contraceptive or hormonal treatment started more than 1 year prior); Medications that may affect test results as deemed by the investigator.","ALL","35 Years",{"count":59,"type":22},20,[25],"Prospective, spontaneous, open-label pre-market clinical trial with a single injection session; monitoring visits at baseline and 60 days post-treatment.\n\nTwo visits will be conducted during the study:\n\n* a baseline visit, during which the first injection will be administered\n* a final visit, 60 days after the baseline visit, for final assessment\n\nThe experimental design involves injection into the deep subdermal layer with the investigational product during the baseline visit, following the study procedure assessments.\n\nTypically, 0.9 ml per side of the face is administered using the retrograde fan technique.\n\nThe study duration is 2 months; safety evaluation will be conducted using non-invasive instrumental assessments such as skin hydration (corneometry) and medical device safety and subjective assessments (see below).",[28,63,64],"Volume Deficiency in the Mid-Face","Wrinkles","2026-02-12",{"date":67,"type":41},"2026-02-17",{"date":69,"type":22},"2026-03",{"date":71,"type":22},"2026-05",{"name":73,"class":74},"303 Pharma s.r.l.","INDUSTRY",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":56,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":49},"100541913","pre-marketing-trial-to-assess-safety-and-efficacy-of-volumizing-filler-based-on-hyaluronic-acid-and-recombinant-collagen-100541913","NCT06336044","Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'","\"Clinical and Instrumental Evaluation of the Safety and Bio-revitalizing Effect on the Face of the Medical Device 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'\"","Inclusion Criteria:\n\n* all sexes\n* caucasic\n* 18 to 70 years\n* non smoker\n\nExclusion Criteria:\n\n* Pregnancy\n* milking\n* smoker\n* alcohol or drugs abuse\n* change of BMI during the study\n* previous facial surgery, implants, permanent treatments\n* sensitivity to the product\n* dermatological difficult frame\n* health weakness\n* treated with anticoagulants, antihistaminics, corticosteroids, antidepressants and other drugs impacting on the results","18 Years","70 Years",{"count":85,"type":22},40,[25],"Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 40 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events",[89,90,28],"Wrinkle","Scar",[92,93,94,64],"hyaluronic acid","Collagen","Filler","RECRUITING","2026-01-22",{"date":98,"type":41},"2026-01-26",{"date":100,"type":22},"2026-02",{"date":102,"type":22},"2026-06",{"name":104,"class":74},"Taumedika s.r.l.",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":56,"minAge":111,"maxAge":19,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":49},"100610186","long-term-efficacy-and-duration-of-mfu-v-at-multiple-depths-and-at-15-mm-100610186","NCT07224308","Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm","Inclusion Criteria:\n\n* Male or female subjects between 25 and 65 years of age at the time of screening.\n\nPresence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and\u002For neck that is appropriate for improvement with non-invasive MFU-V treatment.\n\nSkin condition not advanced enough to require surgical correction.\n\nWillingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.\n\nAbility and willingness to comply with all study visits, procedures, and follow-up requirements.\n\nSufficient English language proficiency to understand study instructions and complete questionnaires.\n\nFor participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.\n\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\n* Male or female subjects between 25 and 65 years of age at the time of screening.\n\nPresence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and\u002For neck that is appropriate for improvement with non-invasive MFU-V treatment.\n\nSkin condition not advanced enough to require surgical correction.\n\nWillingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.\n\nAbility and willingness to comply with all study visits, procedures, and follow-up requirements.\n\nSufficient English language proficiency to understand study instructions and complete questionnaires.\n\nFor participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.\n\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\nActive systemic or local skin disease (e.g., eczema, psoriasis, dermatitis, infection) that may affect wound healing or the evaluation of results.\n\nScarring, tattoos, or significant pigmentary alterations in the planned treatment areas.\n\nMetallic implants or other implanted electronic devices (e.g., pacemakers) in or near the treatment area.\n\nOpen wounds, lesions, active herpes simplex, or active cystic\u002Fsevere inflammatory acne in the treatment area.\n\nUse of isotretinoin or other oral retinoids within the past 12 months or planned use during the study.\n\nMicrodermabrasion or medical-grade glycolic acid treatments to the treatment area within 2 weeks prior to participation.\n\nDeep dermal scarring, thick sebaceous skin, or severe solar elastosis in the treatment area that may interfere with treatment or evaluation.\n\nIntention to gain or lose ≥ 2 BMI units during the 12-month study period.\n\nKnown allergy or hypersensitivity to any component of the device or ultrasound coupling gel.\n\nHistory of chronic drug or alcohol abuse or opioid dependence.\n\nRecent aesthetic procedures to the lower face, submentum, or neck that may confound study outcomes (e.g., fillers, neurotoxins, lasers, threads, RF, ultrasound) within the protocol-specified washout period.\n\nParticipation in another clinical study involving an investigational device or drug within 30 days prior to treatment.\n\nPregnancy, breastfeeding, or plans to become pregnant during the study.\n\nAny condition that, in the opinion of the investigator, would increase risk or interfere with study participation or data interpretation.","25 Years",{"count":59,"type":22},[25],"The goal of this clinical trial is to evaluate the long-term safety and effectiveness of Ultherapy Prime (MFU-V) for improving lines, wrinkles, laxity, and crepiness of the lower face, submentum, and neck. The study will enroll adult male and female subjects aged 25-65 with moderate to severe lower-face and neck skin laxity who are appropriate candidates for non-invasive ultrasound treatment.\n\nThe main questions this study aims to answer are:\n\nDoes Ultherapy Prime delivered at multiple depths compared to a single-depth (1.5 mm) treatment improve clinical lifting, tightening, and smoothing of the lower face and neck over a 12-month period?\n\nDoes treatment with Ultherapy Prime stimulate measurable improvements in collagen-related skin quality, patient satisfaction, and investigator-assessed aesthetic outcomes?\n\nBecause the study includes two treatment approaches, researchers will compare a multi-depth MFU-V treatment protocol versus a single-depth (1.5 mm) MFU-V treatment protocol to determine whether multi-depth energy delivery provides superior or longer-lasting clinical improvement.\n\nWhat Participants Will Do\n\nParticipants will:\n\nAttend a total of 5 study visits over 12 months (Screening\u002FTreatment, 1-month, 3-month, 6-month, and 12-month follow-ups).\n\nUndergo a single Ultherapy Prime treatment session at either multiple depths or at the 1.5 mm depth only.\n\nComplete standardized photography, including 2D and 3D images, at all timepoints.\n\nParticipate in clinical assessments, including GAIS scoring, cutometer elasticity measurements (if applicable), and investigator- and patient-reported satisfaction scales.\n\nFollow pre-visit requirements, including:\n\nNo moisturizers, lotions, or topical products on the treatment area before each visit\n\nNo hair in the treatment area (shave the day prior if needed)\n\nComplete questionnaires evaluating satisfaction, comfort, and perceived treatment benefits.\n\nAdhere to follow-up schedules, avoiding elective aesthetic procedures to the lower face, submentum, or neck during the study period.",[28],"2025-10-31",{"date":118,"type":41},"2025-11-04",{"date":120,"type":41},"2025-10-24",{"date":122,"type":22},"2026-12-30",{"name":124,"class":48},"The Levine Center for Plastic Surgery",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":56,"minAge":111,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100609574","evaluate-the-safety-and-efficacy-of-a-topical-serum-age-serum-in-improving-visible-signs-of-aging-100609574","NCT07216352","Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging","Open-label Study Evaluating the Safety and Efficacy of AGE Serum in Non-menopausal Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.\n2. Adult men and women aged 25-50 years.\n3. Fitzpatrick skin types I-IV.\n4. Current treatment with a stable dose of GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least last 6 months.\n5. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n6. Subjects in good general health based on the investigator's judgment and medical history.\n7. Negative urine pregnancy test result at the time of study entry (if applicable).\n8. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\nA. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partners must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n\nB. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n2. Current menopausal state.\n3. Any uncontrolled systemic disease.\n4. Current use of other GLP-1 agonist therapy aside from the GLP-1 agonist class of medications (Ozempic, Rybelsus, or Wegovy).\n5. History of autoimmune connective tissue disease.\n6. Current use of immunosuppressive medication.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis or active infection in the proposed treatment area.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n10. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment.\n11. Subjects with scarring in the treatment areas, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n12. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n13. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding.\n14. Inability to ambulate following the procedure.\n15. History of lidocaine and\u002For epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n16. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n17. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.","50 Years",{"count":134,"type":22},25,[25],"The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be conducted in non-menopausal female and male subjects who are on glucagon-like peptide-1 (GLP-1) agonist therapy for weight loss.",[28],[139,33,34,35,36],"glp1",{"date":141,"type":41},"2025-10-28",{"date":143,"type":22},"2025-10-25",{"date":145,"type":22},"2026-05-30",{"name":47,"class":48},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":111,"maxAge":19,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":155,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":49},"100609681","phase-2-assess-impact-of-poly-l-lactic-acid-on-glp1-subjects-100609681","NCT07217743","Assess Impact of Poly-L-lactic Acid on GLP1 Subjects","Prospective, Single Center, Open-label Study Assessing Impact of Poly-L-lactic Acid on Adipogenesis in Patients on Glucagon-like Peptide-1 Agonists","Inclusion Criteria:\n\n1. Adult women aged 25-65 years.\n2. Fitzpatrick skin types I-IV.\n3. Presence of mild to moderate skin laxity of abdomen, as determined by clinical investigators.\n4. Stable weight for 3 months, with body mass index (BMI) of 27 or less.\n5. Current treatment with a stable dose of GLP-1 agonist medication for at least the last 6 months, for 15 of the enrolled subjects. Remaining 5 subjects should not be taking or have a history of taking a GLP-1 agonist medication, and should not be planning to take a GLP-1 in the foreseeable future.\n6. Must be willing to sign a photography release and ICF, and complete the entire course of the study.\n7. Subjects in good general health based on investigator's judgment and medical history.\n8. Negative urine pregnancy test result at the time of study entry (if applicable).\n9. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n   1. Acceptable forms of birth control are: oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device\u002Fcoil, double-barrier methods (e.g., sponge, spermicide, or condoms). Abstinence and\u002For vasectomized partner must agree to a second acceptable method of birth control (double-barrier) should the subject become sexually active.\n   2. A female is considered of non-childbearing potential if she is: postmenopausal (no menses for at least 12 months), without a uterus (hysterectomy) and\u002For both ovaries (oophorectomy), or bilateral tubal ligation.\n\nExclusion Criteria:\n\n1. The presence of severe abdominal skin laxity as determined by clinical investigators.\n2. Still actively losing weight.\n3. Pregnancy or planned pregnancy during the study or currently breastfeeding.\n4. Any uncontrolled systemic disease.\n5. History of autoimmune connective tissue disease.\n6. Current use of immunosuppressive medication.\n7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n8. Active dermatitis or active infection in the proposed treatment area.\n9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.\n10. Any investigational treatment for skin quality of the abdomen during the 12-month period before the study treatment\n11. Creams\u002Fcosmeceuticals and\u002For home therapies for the prevention or treatment of skin quality in the treatment area during the 1-month period before study treatment\n12. Subjects with scarring in the treatment areas, including laparoscopic or abdominal surgery scars, which in the opinion of the investigator could impact results. Subjects with a history of keloids will be excluded.\n13. Subjects who spray tanned or used sunless tanners in the treatment areas 1-month prior to study treatment.\n14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and\u002For current pregnancy or breastfeeding .\n15. Inability to ambulate following the procedure.\n16. History of lidocaine and\u002For epinephrine sensitivity deemed by the investigator to preclude subject from enrolling into study.\n17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.\n18. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",{"count":59,"type":22},[156],"PHASE2","Clinical trial to evaluate treatments of double-dilute poly-L-lactic acid on abdominal skin laxity in GLP1 patients versus non GLP1 patients.",[28],[160,161,139,162],"laxity","loose skin","abdominal laxity","2025-10-14",{"date":165,"type":41},"2025-10-16",{"date":167,"type":22},"2025-10-27",{"date":169,"type":22},"2026-10-31",{"name":47,"class":48}]